Researchers at the Autonomous University of Barcelona (UAB), in collaboration with the Sant Pau Research Institute and the CIBER-BBN, have made a groundbreaking advancement in cancer treatment. They have successfully developed micromaterials composed solely of proteins, which have the ability to deliver nanoparticles targeting specific cancer cells over an extended period, ultimately leading to their destruction.
Professor Antonio Villaverde from the Institute of Biotechnology and Biomedicine of the Department of Genetics and Microbiology, UAB, led the team in creating self-contained micromaterials made entirely of proteins. The technology used for their fabrication, patented by the researchers, mimics the natural secretory granules found in the human endocrine system. These micromaterials are formed by chains of amino acids known as polypeptides, which function as nanoparticles released and directed towards specific types of cancer cells for selective destruction.
The research team conducted in-depth analysis of the molecular structure of these materials and the dynamics behind the secretion process, both in vitro and in vivo. In an animal model of CXCR4+ colorectal cancer, the system demonstrated high performance upon subcutaneous administration, with the released protein nanoparticles accumulating in tumor tissues more efficiently than when administered in blood.
Professor Antonio Villaverde emphasized the significance of this accumulation, stating that it offers a new way to ensure high local drug levels and better clinical efficacy, while minimizing undesired side effects. This development holds the potential to enhance drug efficiency and patient comfort in the treatment of colorectal cancer, all while reducing undesired side effects.
